Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)
Go back to Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)| (NASDAQ: IONS) | Delayed: 44.90 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.90 | 52 Week High | $62.68 | |||
| Open | $44.90 | 52 Week Low | $19.59 | |||
| Day High | $44.90 | P/E | N/A | |||
| Day Low | $44.90 | EPS | $0.00 | |||
| Volume | 4,663 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 27.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.74 | 52 Week High | $37.39 | |||
| Open | $27.74 | 52 Week Low | $28.25 | |||
| Day High | $27.74 | P/E | 16.81 | |||
| Day Low | $27.74 | EPS | $1.65 | |||
| Volume | 12,910 | |||||

